Alexion Pharmaceuticals
Headquartered in Cheshire, Connecticut (USA), Alexion is global biopharmaceutical company focused on the development and delivery of life-transforming therapies for patients with severe and life-threatening rare disorders.
Financial Data
-
31st Dec 19 Source: CRO
- €2.5 billion turnover
-
€1.5 billion
profit - 400 employees
-
31st Dec 18 Source: CRO
- €2.3 billion turnover
-
€1.3 billion
profit - 500 employees
- 5 more years available »
Ranking
By Turnover
(€2.5 billion)- 47th in Top Companies
- 10th in Health
- 6th in Pharma
By Employees
(400)- 429th in Top Companies
- 65th in Health
- 39th in Pharma
- 400
- €2.5 billion
Employees
- Shane Doyle Senior vice president
Latest News
- 8:42pm Rolls-Royce seeks bids in England and Wales for site to make small nuclear power plants
- 2:22pm Germany’s Lufthansa in talks to buy 40% stake in Italy’s ITA Airways
- 12:56pm Pay freeze for Aer Lingus ground staff proposed until 2024
- Jan 22 Law firm Mason Hayes & Curran posts 23% surge in fee income to €98m
- Jan 21 US judge rules against Paddy Cosgrave over investment fund dispute